*Read Disclaimer Sponsored Content
{{current_date_full}} | Unsubscribe
Hello!
New Alert: GT Biopharma, Inc. (NASDAQ: GTBP)
GTBP is our brand new NASDAQ breakout alert.
Yesterday the company announced massive news and started what could be just the beginning of a big move higher.
In June, the company traded over 3.00…
That’s over 200% from here.
But it doesn’t have to go up that high to experience double- or triple-digit gains.
GTBP has a 50 day moving average of 1.10.
A breakout and close above this level could present increased upside.
The momentum may already be in place.
With a chart setup pointing to a breakout higher.
GTBP is a NASDAQ listed “clinical stage biopharmaceutical company”.
GTBP is “focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell engager platform”.
The company’s “TriKE® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells”.
GTBP has an “exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology”.
CAR T-cell therapy is a personalized form of immunotherapy that trains your own immune cells to recognize and destroy cancer.
It can be a powerful option for treating certain hard-to-treat blood cancers, especially when other treatments are no longer effective.
However, as the company explains, “CAR-T therapy can require an individual approach that is expensive, can be time consuming, and may be difficult to apply on a large scale.”
The company believes there is “an unmet need for targeted off-the-shelf therapies that can be used on a stand-alone basis, can augment current monoclonal antibody therapeutics, and can be used in conjunction with more traditional cancer therapy”.
To accomplish this goal, GTBP has “generated a pipeline of clinical and non-clinical product candidates consisting of tri-specific killer engagers, or TriKEs, designed to target natural killer (NK) cells and tumor cells”.
GTBP believes their “product candidates have the potential to overcome some of the limitations of CAR-T therapy and other antibody therapies”.
“Unlike full-length tri-specific antibodies, TriKEs are small single-chain fusion proteins that bind the CD16 receptor of NK cells using nanobody technology, which has been shown in preclinical studies to produce a more potent and lasting response.”
Additionally, “these product candidates may have an attractive biodistribution as a consequence of their smaller size – a factor that is expected to be important in the treatment of solid tumors”.
“TriKEs are also designed to be non-immunogenic, have quick clearance properties, and can be engineered rapidly to target a variety of tumor antigens.”
GTBP believes “these attributes make them an ideal pharmaceutical platform for potentiated NK cell-based immunotherapies”.
Here is the company’s “TriKE® Clinical Pipeline”:
“GTB-3650 TriKE®”
“The company plans on releasing more detailed results later in 2025 following enrollment and completion of additional dose cohorts. The trial plans to evaluate GTB-3650 in up to seven cohorts and GTB-3650 will be dosed in 72-hour continuous infusions in two-week blocks, two weeks on and two weeks off, for up to four months based on clinical benefit. The trial will assess safety, pharmacokinetics, pharmacodynamics, in vivo expansion of endogenous patient NK cells and clinical activity.”
“GTB-5550 TriKE®”
“GTB-5550 clinical material has been manufactured, is scheduled to be vialed this summer and FDA submission is planned for Q4 2025.”
“Based on supportive preclinical data, this will be the first TriKE® tested with more patient friendly subcutaneous dosing.”
“The clinical trial is planned to include several solid tumors including breast cancer, lung cancer, ovarian cancer, head and neck cancer, pancreatic cancer, bladder cancer and prostate cancer. Preclinical studies are ongoing to evaluate activity in multiple myeloma and brain tumors planning for separate trials in these settings.”
“GTB-7550 TriKE®”
“Based on its early preclinical activity targeting normal B-cells, studies are ongoing to develop GTB-7550 in autoimmune disease. We are evaluating manufacturing bids for production of clinical material in 2026 with plans for FDA submission thereafter.”
“GTB-3550 TriKE® (discontinued)”
“GTB-3550 and the 1st generation platform was discontinued after strong data suggested that the 2nd generation TriKE was more potent and exhibited better preclinical anti-tumor activity with camelid nanobody technology and wild type IL-15.”
In August, the company announced:
“GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2”
Here are the highlights from this press release:
“The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observed”
“The company plans on releasing initial Phase 1 results later in 2025 following completion of additional dose cohorts”
In addition, the company also announced:
“GT Biopharma Reports Second Quarter 2025 Financial Results”
Here are the highlights from this press release:
“GTB-3650 TriKE® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2’s formal safety review, it has advanced into Cohort 3 and initiated dosing of the fifth patient in the study; initial Phase 1 data expected later in 2025”
“GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in Q4 2025; recent peer-reviewed publication highlights the pre-clinical anti-tumor activity of GTB-5550 against head and neck cancer”
“Cash of approximately $5.3 million as of June 30, 2025, anticipated to be sufficient to fund operations into Q1 2026”
Here are some of the company’s comments from this press release:
“We are pleased with the enrollment momentum in our Phase 1 clinical trial evaluating GTB-3650 in cancer patients, which continues to advance on schedule,” said Michael Breen, Executive Chairman and Chief Executive Office of GT Biopharma. "Moving into the third dose cohort after a successful safety review and encouraging early evidence of immunological activity, mark important steps forward in the development of GTB-3650. We look forward to sharing more data later this year to reinforce the ability of our TriKE constructs to activate endogenous NK cells, and the potential for broader utility with other targets to treat solid tumors (GTB-5550) and autoimmune indications (GTB-7550)."
In addition, on Monday, the company announced:
“GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit”
“announced that Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma, will be participating in the Centurion One Capital 3rd Annual Bahamas Summit at the Rosewood Baha Mar Hotel from Tuesday, October 28th to Wednesday, October 29th, 2025, in Nassau, Bahamas.”
On Wednesday, the company announced very big breaking news that could continue to be a growth catalyst for the company.
Here is the news from yesterday:
“GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies”
Here are the highlights from this press release:
“The Company is well on track with Phase 1 enrollment now that both patients in Cohort 3 have successfully initiated treatment with no evidence of dose-limiting toxicities or tolerability concerns to date”
“The first patient in Cohort 3 has shown promising evidence of immune activation consistent with levels of activity observed in patients from the previous two lower-dose cohorts; additional update anticipated by year-end”
“Upon successful completion of the Cohort 3 safety assessment, the trial will continue to dose escalate with initiation of Cohort 4 dosing planned by year-end 2025, and flexibility to dose up to 7 cohorts if necessary; additional data updates anticipated in Q1 2026”
GTBP could be positioned for increased growth potential.
Make sure to do your own due diligence.
Happy Trading!
SmallCapStocks Team
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
DISCLAIMER:
You should read and understand this disclaimer in its entirety before joining the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.
Owners and operators of the Publisher have been compensated seven thousand dollars by bank wire transfer on 10/8/25 for the distribution of this advertisement about GTBP dated 10/9/25. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.
You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at [email protected] to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link:
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.